JP2022519341A5 - - Google Patents
Info
- Publication number
- JP2022519341A5 JP2022519341A5 JP2021539922A JP2021539922A JP2022519341A5 JP 2022519341 A5 JP2022519341 A5 JP 2022519341A5 JP 2021539922 A JP2021539922 A JP 2021539922A JP 2021539922 A JP2021539922 A JP 2021539922A JP 2022519341 A5 JP2022519341 A5 JP 2022519341A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- sequence
- antibody fragment
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024213235A JP7788118B2 (ja) | 2019-01-13 | 2024-12-06 | ヒトネクチン－２に特異的な抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962791808P | 2019-01-13 | 2019-01-13 | |
| US62/791,808 | 2019-01-13 | ||
| PCT/IL2020/050047 WO2020144697A1 (en) | 2019-01-13 | 2020-01-13 | Antibodies specific to human nectin-2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024213235A Division JP7788118B2 (ja) | 2019-01-13 | 2024-12-06 | ヒトネクチン－２に特異的な抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519341A JP2022519341A (ja) | 2022-03-23 |
| JP2022519341A5 true JP2022519341A5 (enExample) | 2023-01-20 |
| JP7606706B2 JP7606706B2 (ja) | 2024-12-26 |
Family
ID=69701225
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539922A Active JP7606706B2 (ja) | 2019-01-13 | 2020-01-13 | ヒトネクチン－２に特異的な抗体 |
| JP2024213235A Active JP7788118B2 (ja) | 2019-01-13 | 2024-12-06 | ヒトネクチン－２に特異的な抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024213235A Active JP7788118B2 (ja) | 2019-01-13 | 2024-12-06 | ヒトネクチン－２に特異的な抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12545727B2 (enExample) |
| EP (1) | EP3908372A1 (enExample) |
| JP (2) | JP7606706B2 (enExample) |
| KR (1) | KR20210117277A (enExample) |
| CN (2) | CN118878685A (enExample) |
| AU (1) | AU2020207664B2 (enExample) |
| CA (1) | CA3125962A1 (enExample) |
| IL (1) | IL284807B2 (enExample) |
| WO (1) | WO2020144697A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240152879A (ko) | 2022-02-28 | 2024-10-22 | 넥틴 테라퓨틱스 리미티드 | 넥틴-2에 대한 인간화 항체 및 이의 약물 접합체 |
| CN116063498A (zh) * | 2022-04-27 | 2023-05-05 | 博际生物医药科技(杭州)有限公司 | 单域抗Nectin-4抗体 |
| EP4716696A1 (en) | 2023-05-23 | 2026-04-01 | Fondazione Per L'Istituto Oncologico Di Ricerca (IOR) | Monospecific and bispecific antibodies and antibody-drug conjugates targeting nectin2 (cd112) and psma |
| WO2024240899A1 (en) | 2023-05-23 | 2024-11-28 | Universite De Geneve | Dual targeting of psma and nectin2 in prostate cancer |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| KR20250161706A9 (ko) * | 2024-05-08 | 2026-02-03 | 아주대학교산학협력단 | Nectin-2에 특이적으로 결합하는 항체 및 이의 용도 |
| KR20250161707A (ko) * | 2024-05-08 | 2025-11-18 | 아주대학교산학협력단 | Nectin-2에 결합하는 항체 약물 접합체 및 이의 용도 |
| KR20250175021A (ko) | 2024-06-05 | 2025-12-16 | 아주대학교산학협력단 | Nectin-2에 특이적으로 결합하는 인간화 항체 및 이의 용도 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| DE69309472T2 (de) | 1992-01-23 | 1997-10-23 | Merck Patent Gmbh, 64293 Darmstadt | Fusionsproteine von monomeren und dimeren von antikörperfragmenten |
| EP0787185A2 (en) | 1994-10-20 | 1997-08-06 | MorphoSys AG | Targeted hetero-association of recombinant proteins to multi-functional complexes |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2222055A1 (en) | 1995-05-23 | 1996-11-28 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Multimeric proteins |
| US5719867A (en) | 1995-06-30 | 1998-02-17 | Scientific-Atlanta, Inc. | Plural telephony channel baseband signal demodulator for a broadband communications system |
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| US20090142346A1 (en) | 2005-10-07 | 2009-06-04 | Takeda Pharmaceutical Company Limited | Preventive/Remedy for Cancer |
| JPWO2008044754A1 (ja) * | 2006-10-06 | 2010-02-18 | 武田薬品工業株式会社 | 癌の予防・治療剤 |
| WO2008126847A1 (ja) | 2007-04-11 | 2008-10-23 | Takeda Pharmaceutical Company Limited | 癌の予防・治療剤 |
| CN104011925A (zh) | 2011-12-27 | 2014-08-27 | 株式会社Lg化学 | 锂二次电池及其制备方法 |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| EP3344658B1 (en) * | 2015-09-02 | 2022-05-11 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Antibodies specific to human t-cell immunoglobulin and itim domain (tigit) |
| US10407484B2 (en) | 2015-09-02 | 2019-09-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for modulating T-cell mediated immune response |
| CN108513576A (zh) | 2015-09-14 | 2018-09-07 | 高山免疫科学股份有限公司 | 可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗 |
| CA3015619A1 (en) | 2016-03-01 | 2017-09-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human poliovirus receptor (pvr) |
| US20190224339A1 (en) | 2016-04-29 | 2019-07-25 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| LT3535392T (lt) * | 2016-11-02 | 2024-04-25 | Universität Basel | Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje |
| KR20240152879A (ko) | 2022-02-28 | 2024-10-22 | 넥틴 테라퓨틱스 리미티드 | 넥틴-2에 대한 인간화 항체 및 이의 약물 접합체 |
-
2020
- 2020-01-13 EP EP20707330.5A patent/EP3908372A1/en active Pending
- 2020-01-13 CN CN202411054370.3A patent/CN118878685A/zh active Pending
- 2020-01-13 JP JP2021539922A patent/JP7606706B2/ja active Active
- 2020-01-13 WO PCT/IL2020/050047 patent/WO2020144697A1/en not_active Ceased
- 2020-01-13 IL IL284807A patent/IL284807B2/en unknown
- 2020-01-13 AU AU2020207664A patent/AU2020207664B2/en active Active
- 2020-01-13 CN CN202080009083.4A patent/CN113301954B/zh active Active
- 2020-01-13 CA CA3125962A patent/CA3125962A1/en active Pending
- 2020-01-13 KR KR1020217023368A patent/KR20210117277A/ko active Pending
- 2020-01-13 US US17/421,885 patent/US12545727B2/en active Active
-
2024
- 2024-12-06 JP JP2024213235A patent/JP7788118B2/ja active Active
-
2025
- 2025-12-23 US US19/432,034 patent/US20260116971A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022519341A5 (enExample) | ||
| JP2021522801A5 (enExample) | ||
| KR102812377B1 (ko) | 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체 | |
| JP2024088696A (ja) | ヒトネクチン４に特異的な抗体 | |
| CN110511278B (zh) | 抗b7-h6抗体、融合蛋白及其使用方法 | |
| JP2019511212A5 (enExample) | ||
| US20260116971A1 (en) | Antibodies specific to human nectin-2 | |
| JP2018532383A5 (enExample) | ||
| JP2018521008A (ja) | 腫瘍形成を処置するための治療用組成物および治療方法 | |
| US12110337B2 (en) | Anti-CD27 antibodies and uses thereof | |
| HUE035865T2 (en) | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use | |
| TW201625270A (zh) | 用於治療贅瘤形成的治療組合及方法 | |
| JP2021512107A5 (enExample) | ||
| US20230183342A1 (en) | Antibodies to nkp46 and constructs thereof for treatment of cancers and infections | |
| US11325976B2 (en) | Anti-programmed death-ligand 1 (PD-L1) antibodies and therapeutic uses thereof | |
| JP2023517794A (ja) | 抗ｔｎｆｒ２抗体及びその使用 | |
| KR20240038769A (ko) | 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법 | |
| RU2021118587A (ru) | Антитела, специфичные в отношении нектина-2 человека | |
| RU2020133629A (ru) | Антитела, специфичные к нектину-4 человека | |
| HK40079353A (en) | Antibodies specific to human poliovirus receptor (pvr) | |
| JP2024540320A5 (enExample) | ||
| HK40060175A (en) | Antibodies specific to human nectin-2 | |
| HK40090273A (zh) | 用於治疗癌症和感染的针对nkp46的抗体及其构建体 | |
| NZ745564B2 (en) | Antibodies specific to human poliovirus receptor (pvr) |